Veracyte (Veracyte) Total Current Assets : $290.4 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Veracyte Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Veracyte's total current assets for the quarter that ended in Mar. 2024 was $290.4 Mil.

Veracyte Total Current Assets Historical Data

The historical data trend for Veracyte's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Total Current Assets Chart

Veracyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

187.69

375.68

243.10

248.64

285.62

Veracyte Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															251.50	259.48	271.16	285.62	290.42

Veracyte Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Veracyte's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	216.454	+	40.378	+	16.128	+	12.661
	=	285.6

Veracyte's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	209.188	+	46.665	+	18.328	+	16.237
	=	290.4

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Veracyte (NAS:VCYT) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Veracyte's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	209.188	-	81.424	+	0.75 * 46.665	+	0.5 * 18.328
=	171.9

Veracyte Total Current Assets Related Terms

Thank you for viewing the detailed overview of Veracyte's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Veracyte (Veracyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (NAS:VCYT) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

12V:Germany

Address

6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.veracyte.com

Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.

Executives

Phillip G. Febbo	officer: Chief Scientific & Med Officer	C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
John Leite	officer: Chief Commercial Officer-CLIA	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Evan/ Fa Jones	director	C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
John L Bishop	director
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bonnie H Anderson	director, officer: President & CEO	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Karin Eastham	director	C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Giulia C Kennedy	officer: Chief Scientific & Med Officer	338 MAIN STREET #26E, SAN FRANCISCO CA 94105
Eliav Barr	director	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Jens Holstein	director	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Stapley	officer: Chief Executive Officer	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Kevin K Gordon	director	155 S LIMERICK RD, LIMERICK PA 19468
Jonathan Wygant	officer: VP, Chief Accounting Officer	3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Annie Mcguire	officer: SVP, General Counsel	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Rebecca Chambers	officer: Chief Financial Officer	3052 ORCHARD DR., SAN JOSE CA 95134